Carlo Bodenizza

Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromes

Pellegrino Musto, Francesco Lanza, Enrico Balleari et al. · British Journal of Haematology · 2004 · 97 citations · Full text

Medicine, Hematology, Pharmacology +12

Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes

Pellegrino Musto, Antonietta Falcone, Grazia Sanpaolo et al. · British Journal of Haematology · 2003 · 49 citations · Full text

Medicine, Hematology, Pharmacology +12

Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.

Pellegrino Musto, Rosella Matera, Maria Marta Minervini et al. · PubMed · 1994 · 44 citations

Medicine, Hematology, Immunology +12

Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial

Pellegrino Musto, Antonietta Falcone, Grazia Sanpaolo et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2003 · 34 citations

Medicine, Pharmacology, Pharmacotherapy +14

Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.

Pellegrino Musto, Grazia Sanpaolo, Giovanni D’Arena et al. · PubMed · 2001 · 27 citations

Medicine, Hematology, Pharmacotherapy +11